Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Clinical trial NCT03552276 · COMPLETED
Trial details
- NCT number
- NCT03552276
- Sponsor
- Sun Pharmaceutical Industries Limited
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-11
- Primary completion
- 2023-09-18
- Enrollment
- 281
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.